Analyze Your Search

Hints:

  • Action links for each search result record
    • Bookmark: Allows you to Bookmark the page for easy future retrieval 
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • More Info: Shows full summary of content record
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Follow" button to the right of the search box. 
Cancer Biomarkers and Genetics
  Follow Topic   Edit Search

Genetic testing may encompass the analysis of gene(s), exomes, or even the entire genome. Genetic testing conducted to identify germline (inherited) gene mutations is typically performed on a blood, mouthwash, buccal swab, or banked DNA specimen. The purpose of germline genetic testing in the oncology setting is to identify the underlying genetic basis for the cancer predisposition in the family and subsequently use this information to guide treatment, follow-up, and make genetic testing available to at-risk family members. From the Washington Manual of Oncology.

Your search returned 5 results
from the time period: last 30 days.
Sort by Relevance / Date Group By Journal / No Grouping
JAMA 
CitationSubset: AIM. CitationSubset: IM. DescriptorName: Aged. DescriptorName: Biomarkers, Tumor. DescriptorName: DNA Mutational Analysis. DescriptorName: DNA, Neoplasm. DescriptorName: Female. DescriptorName: Genetic Predisposition to Disease. DescriptorName: Genetic Testing. DescriptorName: Germ-Line Mutation. DescriptorName: Humans. DescriptorName: Male. DescriptorName: Middle Aged. DescriptorName: Neoplasms. DescriptorName: Phenotype. DescriptorName: Prospective Studies. AbstractText: Guidelines for cancer genetic testing based on family history may miss clinically actionable genetic changes ...
Oncology (12)
Neoplasms (20), Colonic Neoplasms (1), more mentions
Proceedings of the National Academy of Sciences of the United States of America 
The earlier diagnosis of cancer is one of the keys to reducing cancer deaths in the future. Here we describe our efforts to develop a noninvasive blood test for the detection of pancreatic ductal adenocarcinoma. We combined blood tests for KRAS gene mutations with carefully thresholded protein biomarkers to determine whether the combination of these markers was superior to any single marker. The cohort tested included 221 patients with resectable pancreatic ductal adenocarcinomas and 182 control patients without known cancer. KRAS mutations were detected in the plasma of 66 patients (30%), and every mutation found in the plasma was identical to that subsequently found in the patient's primary tumor (100% concordance). The use of KRAS in conjunction with four thresholded protein biomarkers increased the sensitivity to 64%. Only one of the 182 plasma samples from the control cohort was positive for any of the DNA or protein biomarkers (99.5% specificity). This combinatorial approach may prove useful for the earlier detection of many cancer types.
Oncology (6)
Neoplasms (8), Adenocarcinoma (2), Pancreatic Neoplasms (1), more mentions
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 
AbstractText: The role of serum tumor markers in the modern management of advanced non-small cell lung cancer remains poorly described ... nadir occurred in 53% of systemic and 22% of CNS only progression AbstractText: Serum tumor markers are commonly elevated in lung adenocarcinoma regardless of driver oncogene... Keyword: serum tumor marker.
Oncology (2)
Neoplasms (4), Adenocarcinoma (3), Lung Neoplasms (2), more mentions
Gut 
Notably, ZFP36L2 is associated with super-enhancer in healthy oesophageal mucosa; DNA hypermethylation in its super-enhancer reduced active histone markers in squamous cancer cells, suggesting an epigenetic inactivation of a super-enhancer-associated SCC suppressor AbstractText: These data comprehensively contrast differences between OSCC and OAC at both genomic and ...
Oncology (3)
Neoplasms (3), Squamous Cell Carcinoma (2), Adenocarcinoma (2), more mentions
Oncogene 
Abstract: Circulating tumor DNA (ctDNA) has emerged as a tumor-specific biomarker for the early detection of various cancers. To date, several techniques have been devised to enrich the extremely small amounts of ctDNA present in plasma, but they are still insufficient for cancer diagnosis, especially at the early stage.
Oncology (4)
Neoplasms (6), Colorectal Neoplasms (1), more mentions